Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment

2024-9-12

Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer

2024-9-10

Research progress on the role and mechanism of circular RNA in drug resistance of head and neck squamous cell carcinoma

2024-9-2

The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer

2024-8-19

The uniqueness of ABCB5 as a full transporter ABCB5FL and a half-transporter-like ABCB5β

2024-8-7

Targeting NETosis: nature’s alarm system in cancer progression

2024-7-19

Impact of genetic variants in the solute carrier (<i>SLC</i>) genes encoding drug uptake transporters on the response to anticancer chemotherapy

2024-7-18

Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review

2024-6-26

Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects

2024-6-24

Recent advanced lipid-based nanomedicines for overcoming cancer resistance

2024-6-21

The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer

2024-6-11

Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer

2024-6-3

Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients

2024-5-24

ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

2024-5-23

Chemosensitizing effect of pentoxifylline in sensitive and multidrug-resistant non-small cell lung cancer cells

2024-5-20

Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them

2024-5-14

Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers

2024-5-13

Isocucurbitacin B inhibits glioma growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286a

2024-5-8

Emerging role of MYB transcription factors in cancer drug resistance

2024-4-30

HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs

2024-4-29

The therapeutic potential of circular RNA in triple-negative breast cancer

2024-4-23

Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells

2024-4-9

Dysregulation of calcium homeostasis in cancer and its role in chemoresistance

2024-3-15

Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model

2024-3-14

Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer

2024-3-13

Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implications

2024-2-29

Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors

2024-2-28

Leveraging genomics, transcriptomics and epigenomics to understand chemoimmunotherapy resistance in chronic lymphocytic leukemia

2024-2-28

Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia

2024-2-22

Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer

2024-1-31

Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel

2024-1-31

Targeting T regulatory (T_reg) cells in immunotherapy-resistant cancers

2024-1-12

Acquisition of drug resistance in endothelial cells by tumor-derived extracellular vesicles and cancer progression

2024-1-5

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

2023-12-28

Autophagy-related mechanisms for treatment of multiple myeloma

2023-12-25

Targeting BCL2 pathways in CLL: a story of resistance and ingenuity

2023-11-27

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

2023-11-22

Emerging roles of 3D-culture systems in tackling tumor drug resistance

2023-11-21

Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies

2023-11-17

Unlocking antitumor immunity with adenosine receptor blockers

2023-10-23

Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity

2023-10-17

Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistance

2023-10-16

Drug resistance in glioblastoma: from chemo- to immunotherapy

2023-10-11

Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia

2023-9-26

A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer

2023-9-25

Emerging resistance <i>vs.</i> losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena

2023-9-20

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment

2023-9-4

Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7

2023-9-1

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia

2023-8-17

A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer

2023-8-11